60 likes | 179 Views
Innovative financing. GAVI/09/Olivier Asselin. How AMC works. Donors commit funds to finance the purchase of new vaccines at a pre-agreed price for a certain amount of doses
E N D
Innovative financing GAVI/09/Olivier Asselin
How AMC works • Donors commit funds to finance the purchase of new vaccines at a pre-agreed price for a certain amount of doses • These financial commitments provide the guarantee that manufacturers need to invest in the necessary research and development of the new vaccine. • Manufacturers can participate in the AMC if and when they develop a vaccine that meets specific and stringent criteria and if the vaccine is requested by beneficiary countries • In exchange for the upfront donor funds, manufacturers legally commit to supply their vaccine at a lower price over the long-term. • The long-term price is paid by beneficiary countries and GAVI.
The Pneumococcal AMC pilot • Overarching goal: reduce morbidity and mortality from pneumococcal diseases. • Main objectives: • Bring forward the availability of effective pneumococcal vaccines - scale up of production capacity. • Accelerate development of second generation vaccines that meet developing country needs. • Accelerate vaccine uptake - predictable vaccine pricing for countries and manufacturers. • Test AMC concept
The pneumococcal AMC funding sources $7 AMCfunds AMC Price per Dose Tail price cap $3.50 GAVI funding Country Co-pay ( $0.10 - $0.30 per dose initially) * $0 2 4 6 8 10 Years 1stEligible Vaccine available supplier’s share of AMC funds depleted Supply Commitment Fulfilled 10 yrs * Co-financing levels will be in line with the applicable GAVI co-financing policy. Source: GAVI Alliance, 2009
What does this mean for GAVI countries? Same • Countries express their preference on pneumococcal vaccines • GAVI co-financing and default policies will apply to the AMC without modifications • Vaccines are procured through UNICEF But different • Vaccines will be available in the right quantities to cover demand • Availability of support funding is known years in advance • The price of these vaccines for developing countries is known years before procurement starts
Progress to date & next steps First call for offers September 4th, 2009 legal agreements signed on 12 June 2009 Vaccines could be delivered to countries 2010 SDF v 0.1 published 7th August, 2009 2010 2009 First Supply Agreement potentiallysigned Q1 2010 Design Implementation